Krystal Biotech Q2 2024 Earnings Report $183.92 +1.17 (+0.64%) As of 03/28/2025 04:00 PM Eastern Earnings HistoryForecast Krystal Biotech EPS ResultsActual EPS$0.53Consensus EPS $0.50Beat/MissBeat by +$0.03One Year Ago EPS-$1.25Krystal Biotech Revenue ResultsActual Revenue$70.28 millionExpected Revenue$65.27 millionBeat/MissBeat by +$5.01 millionYoY Revenue Growth+70,283,900.00%Krystal Biotech Announcement DetailsQuarterQ2 2024Date8/5/2024TimeBefore Market OpensConference Call ResourcesConference CallSlide DeckPress ReleaseSEC FilingKRYS Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Slide DeckFull Screen Slide DeckPowered by Remove Ads Krystal Biotech Earnings HeadlinesStocks Showing Improving Market Leadership: Metsera Earns 82 RS RatingMarch 24, 2025 | msn.comShort Interest in Krystal Biotech, Inc. (NASDAQ:KRYS) Decreases By 13.5%March 21, 2025 | americanbankingnews.comHere’s how you could profit from Elon’s NVIDIA partnershipElon Musk recently offered NVIDIA $1 billion... To buy a cluster of their cutting-edge GB200 AI chips. Why? Because Elon is quietly building the most powerful AI supercomputer on the planet. It's called "Project Colossus"...March 31, 2025 | Behind the Markets (Ad)Harrow Shows Market Leadership With Jump To 92 RS RatingMarch 19, 2025 | msn.comWilliam Blair Sticks to Their Hold Rating for Legend Biotech (LEGN)March 12, 2025 | markets.businessinsider.comKrystal Biotech at TD Cowen Conference: Strategic Pipeline ProgressMarch 8, 2025 | uk.investing.comSee More Krystal Biotech Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Krystal Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Krystal Biotech and other key companies, straight to your email. Email Address About Krystal BiotechKrystal Biotech (NASDAQ:KRYS), a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.View Krystal Biotech ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Intuitive Machines Gains After Earnings Beat, NASA Missions AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio?Analysts Lift Archer Aviation Stock Despite Earnings Miss Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025)Morgan Stanley (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
